Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Aug-22 4:27 PM View:  | Sabus Steve M SVP & Chief Commercial Officer | Turning Point Therapeutics,... (TPTX) | 17-Aug-22 | Disposition | 36,667 | $76.00 | $2,786,690.00 | (100%) 36.67K to 0 | |
| 17-Aug-22 4:29 PM View: | Sun Brian SVP & General Counsel | Turning Point Therapeutics,... (TPTX) | 17-Aug-22 | Disposition | 45,000 | $76.00 | $3,420,000.00 | (100%) 45.0K to 0 | |
| 17-Aug-22 4:23 PM View: | Countouriotis Athena President & CEO Director | Turning Point Therapeutics,... (TPTX) | 17-Aug-22 | Disposition | 110,959 | $76.00 | $8,432,880.00 | (100%) 110.96K to 0 | |
| 17-Aug-22 4:26 PM View: | Hirmand Mohammad EVP and Chief Medical Officer | Turning Point Therapeutics,... (TPTX) | 17-Aug-22 | Disposition | 41,284 | $76.00 | $3,137,580.00 | (100%) 41.28K to 0 | |
| 17-Aug-22 4:40 PM View: | George Simeon Director | Turning Point Therapeutics,... (TPTX) | 17-Aug-22 | Disposition | 2,253,660 | $76.00 | $171,278,000.00 | (100%) 2.25M to 0 | |
| 17-Aug-22 4:32 PM View: | Alles Mark J Director | Turning Point Therapeutics,... (TPTX) | 17-Aug-22 | Disposition | 2,000 | $76.00 | $152,000.00 | (100%) 2.0K to 0 | |
| 17-Aug-22 4:31 PM View: | Tombesi Paolo EVP & Chief Financial Officer | Turning Point Therapeutics,... (TPTX) | 17-Aug-22 | Disposition | 29,778 | $76.00 | $2,263,130.00 | (100%) 29.78K to 0 | |
| 29-Jul-22 4:18 PM View: | Tombesi Paolo EVP & Chief Financial Officer | Turning Point Therapeutics,... (TPTX) | 27-Jul-22 | Private Sale | 1,183 | $74.94 | $88,654.00 | (4%) 29.88K to 28.7K | |
| 01-Jun-22 5:02 PM View: | Sabus Steve M SVP & Chief Commercial Officer | Turning Point Therapeutics,... (TPTX) | 31-May-22 | Grant | 36,667 | -- | -- | 100% 0 to 36.67K | |
| 12-Apr-22 6:46 PM View: | Sun Brian SVP & General Counsel | Turning Point Therapeutics,... (TPTX) | 11-Apr-22 | Grant | 45,000 | -- | -- | 100% 0 to 45.0K | |
| 11-Feb-22 6:07 PM View: | Countouriotis Athena President & CEO Director | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Sale | 2,971 | $36.30 | $107,847.00 | (3%) 113.3K to 110.33K | |
| 11-Feb-22 6:10 PM View: | Reich Siegfried EVP & Chief Scientific Officer | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Grant | 13,567 | -- | -- | 353% 3.85K to 17.41K | |
| 11-Feb-22 6:10 PM View: | Reich Siegfried EVP & Chief Scientific Officer | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Sale | 397 | $36.30 | $14,411.10 | (2%) 17.41K to 17.02K | |
| 11-Feb-22 6:09 PM View: | Partridge Andrew John EVP & Chief Commercial Officer | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Grant | 16,283 | -- | -- | 73% 22.3K to 38.58K | |
| 11-Feb-22 6:09 PM View: | North Annette EVP & General Counsel | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Grant | 16,283 | -- | -- | 132% 12.37K to 28.65K | |
| 11-Feb-22 6:07 PM View: | Countouriotis Athena President & CEO Director | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Grant | 62,400 | -- | -- | 123% 50.9K to 113.3K | |
| 11-Feb-22 6:11 PM View: | Tombesi Paolo EVP & Chief Financial Officer | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Grant | 16,283 | -- | -- | 120% 13.6K to 29.88K | |
| 11-Feb-22 6:08 PM View: | Hirmand Mohammad EVP & Chief Medical Officer | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Grant | 33,983 | -- | -- | 453% 7.51K to 41.49K | |
| 11-Feb-22 6:09 PM View: | North Annette EVP & General Counsel | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Sale | 669 | $36.30 | $24,284.70 | (2%) 28.65K to 27.98K | |
| 11-Feb-22 6:09 PM View: | Partridge Andrew John EVP & Chief Commercial Officer | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Sale | 221 | $36.30 | $8,022.30 | (< 1%) 38.58K to 38.36K | |
| 11-Feb-22 6:08 PM View: | Hirmand Mohammad EVP & Chief Medical Officer | Turning Point Therapeutics,... (TPTX) | 09-Feb-22 | Sale | 669 | $36.30 | $24,284.70 | (2%) 41.49K to 40.82K | |
| 31-Aug-21 10:00 PM View: | North Annette EVP, General Counsel & Secty. | Turning Point Therapeutics,... (TPTX) | 30-Aug-21 | Market Option Sale (Planned) | 10,000 | $80.00 | $800,000.00 | (45%) 22.36K to 12.37K | |
| 31-Aug-21 10:00 PM View: | North Annette EVP, General Counsel & Secty. | Turning Point Therapeutics,... (TPTX) | 30-Aug-21 | Option Exercise | 10,000 | $17.00 | $170,000.00 | 81% 12.37K to 22.36K | |
| 27-Jul-21 6:22 PM View: | Tombesi Paolo EVP & Chief Financial Officer | Turning Point Therapeutics,... (TPTX) | 26-Jul-21 | Grant | 13,600 | -- | -- | 100% 0 to 13.6K | |
| 15-Jul-21 5:53 PM View: | Partridge Andrew John EVP & Chief Commercial Officer | Turning Point Therapeutics,... (TPTX) | 14-Jul-21 | Market Sale | 1,869 | $74.90 | $139,988.00 | (8%) 23.64K to 21.77K | 7% |
| 21-Jun-21 9:14 PM View: | Alles Mark J Director | Turning Point Therapeutics,... (TPTX) | 21-Jun-21 | Market Purchase | 2,000 | $81.34 | $162,680.00 | 100% 0 to 2.0K | (< 1%) |
| 16-Jun-21 5:16 PM View: | North Annette EVP, General Counsel & Secty. | Turning Point Therapeutics,... (TPTX) | 15-Jun-21 | Option Exercise | 15,000 | $17.00 | $255,000.00 | 121% 12.37K to 27.36K | |
| 16-Jun-21 5:16 PM View: | North Annette EVP, General Counsel & Secty. | Turning Point Therapeutics,... (TPTX) | 15-Jun-21 | Market Option Sale (Planned) | 15,000 | $77.03 | $1,155,430.00 | (55%) 27.36K to 12.37K | |
| 07-May-21 4:37 PM View: | North Annette EVP, General Counsel & Secty. | Turning Point Therapeutics,... (TPTX) | 06-May-21 | Option Exercise | 5,882 | $17.00 | $99,994.00 | 91% 6.48K to 12.37K | |
| 24-Mar-21 9:54 PM View: | Baker Brian Lee SVP of Finance and Admin. | Turning Point Therapeutics,... (TPTX) | 23-Mar-21 | Option Exercise | 28,435 | $4.67 | $132,906.00 | 691% 4.12K to 32.55K | |
| 24-Mar-21 9:54 PM View: | Baker Brian Lee SVP of Finance and Admin. | Turning Point Therapeutics,... (TPTX) | 23-Mar-21 | Market Option Sale (Planned) | 28,435 | $100.65 | $2,862,080.00 | (87%) 32.55K to 4.12K | |
| 24-Mar-21 9:54 PM View: | Baker Brian Lee SVP of Finance and Admin. | Turning Point Therapeutics,... (TPTX) | 22-Mar-21 | Grant | 1,625 | -- | -- | 65% 2.49K to 4.12K | |
| 09-Mar-21 7:26 PM View: | North Annette EVP, General Counsel & Secty. | Turning Point Therapeutics,... (TPTX) | 08-Mar-21 | Option Exercise | 20,000 | $17.00 | $340,000.00 | 308% 6.48K to 26.48K | |
| 09-Mar-21 7:26 PM View: | North Annette EVP, General Counsel & Secty. | Turning Point Therapeutics,... (TPTX) | 08-Mar-21 | Market Option Sale (Planned) | 20,000 | $109.80 | $2,195,940.00 | (76%) 26.48K to 6.48K | |
| 05-Mar-21 8:56 PM View: | Reich Siegfried EVP & Chief Scientific Officer | Turning Point Therapeutics,... (TPTX) | 04-Mar-21 | Option Exercise | 35,550 | $51.28 | $1,823,000.00 | 925% 3.85K to 39.4K | |
| 05-Mar-21 8:56 PM View: | Reich Siegfried EVP & Chief Scientific Officer | Turning Point Therapeutics,... (TPTX) | 04-Mar-21 | Market Option Sale (Planned) | 35,550 | $105.04 | $3,734,080.00 | (90%) 39.4K to 3.85K | |
| 11-Feb-21 8:28 PM View: | Countouriotis Athena President & CEO Director | Turning Point Therapeutics,... (TPTX) | 11-Feb-21 | Option Exercise | 8,942 | $3.20 | $28,614.40 | 18% 50.2K to 59.14K | |
| 11-Feb-21 8:28 PM View: | Countouriotis Athena President & CEO Director | Turning Point Therapeutics,... (TPTX) | 11-Feb-21 | Market Option Sale (Planned) | 8,942 | $137.38 | $1,228,450.00 | (15%) 59.14K to 50.2K | 2% |
| 11-Feb-21 8:28 PM View: | Countouriotis Athena President & CEO Director | Turning Point Therapeutics,... (TPTX) | 10-Feb-21 | Option Exercise | 25,392 | $3.20 | $81,254.40 | 51% 50.2K to 75.59K | |
| 11-Feb-21 8:28 PM View: | Countouriotis Athena President & CEO Director | Turning Point Therapeutics,... (TPTX) | 10-Feb-21 | Market Option Sale (Planned) | 25,392 | $136.31 | $3,461,120.00 | (34%) 75.59K to 50.2K | 1% |
| 11-Feb-21 8:28 PM View: | Countouriotis Athena President & CEO Director | Turning Point Therapeutics,... (TPTX) | 09-Feb-21 | Option Exercise | 25,666 | $3.20 | $82,131.20 | 51% 50.2K to 75.86K | |
| 11-Feb-21 8:28 PM View: | Countouriotis Athena President & CEO Director | Turning Point Therapeutics,... (TPTX) | 09-Feb-21 | Market Option Sale (Planned) | 25,666 | $138.68 | $3,559,480.00 | (34%) 75.86K to 50.2K | 3% |
| 10-Feb-21 6:03 PM View: | Hirmand Mohammad EVP and Chief Medical Officer | Turning Point Therapeutics,... (TPTX) | 08-Feb-21 | Grant | 6,483 | -- | -- | 2283% 0.28K to 6.77K | |
| 10-Feb-21 5:53 PM View: | Baker Brian Lee SVP of Finance and Admin. | Turning Point Therapeutics,... (TPTX) | 08-Feb-21 | Grant | 1,483 | -- | -- | 147% 1.01K to 2.49K | |
| 10-Feb-21 5:52 PM View: | Countouriotis Athena President & CEO Director | Turning Point Therapeutics,... (TPTX) | 08-Feb-21 | Grant | 22,617 | -- | -- | 82% 27.58K to 50.2K | |
| 10-Feb-21 5:58 PM View: | Larson Yi EVP & Chief Financial Officer | Turning Point Therapeutics,... (TPTX) | 08-Feb-21 | Grant | 4,617 | -- | -- | 171% 2.7K to 7.32K | |
| 10-Feb-21 6:01 PM View: | North Annette EVP, General Counsel & Secty. | Turning Point Therapeutics,... (TPTX) | 08-Feb-21 | Grant | 6,483 | -- | -- | 100% 0 to 6.48K | |
| 10-Feb-21 5:55 PM View: | Reich Siegfried EVP & Chief Scientific Officer | Turning Point Therapeutics,... (TPTX) | 08-Feb-21 | Grant | 3,845 | -- | -- | 100% 0 to 3.85K | |
| 10-Feb-21 5:59 PM View: | Partridge Andrew John EVP & Chief Commercial Officer | Turning Point Therapeutics,... (TPTX) | 08-Feb-21 | Grant | 2,136 | -- | -- | 10% 21.5K to 23.64K | |
| 02-Feb-21 9:47 PM View: | Larson Yi EVP & Chief Financial Officer | Turning Point Therapeutics,... (TPTX) | 02-Feb-21 | Option Exercise | 14,298 | $54.03 | $772,521.00 | 529% 2.7K to 17.0K |
